Access to Drug Treatments

This page has the latest updates about plans to manage the impact of COVID-19 on the Managed Access Agreement (MAA) for nusinersen treatment in England and any other updates from the devolved nations.

It will also cover, or have links to, any updates about access to the other treatments, risdiplam and ZolgensmaTM.


27th March
ZOLGENSMA: REQUEST TO NICE TO INCLUDE appraisal as a therapeutically critical topic in COVID-19 IMPacted Work Programme  

20th March

Nusinersen MAA: Statement from NHS England and NICE


16th March

BIOGEN'S STATEMENT RE: CORONAVIRUS (COVID-19) IMPACT on access to nusinersen
 

13th March

ROCHE’S CLINICAL DEVELOPMENT PROGRAMME STATEMENT RE: CORONAVIRUS (COVID-19) IMPACT on risdiplam trials and global access programme